Page 2 - ஜெமிநை சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors CAMBRIDGE, Mass. (BUSINESS WIRE) Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company’s Board of Directors. “I am pleased to welcome Georges to Gemini’s Board of Directors during this important time in our Company’s maturation, as we advance our lead program into the next stages of clinical development,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. “Georges’ broad management experience and proven track record of commercial and product development success will be invaluable as we continue to advance our pipeline of novel precision medicines.”

United kingdomFrance generalSherri spearGeorges gemayelJoshua mansbachJason meyenburgRoche ltdNational specialty careCompany board of directorsAltus pharmaceuticals incMomenta pharmaceuticalsRaptor pharmaceuticalsFoldrx pharmaceuticalsSupernus pharmaceuticals incSyndexa pharmaceuticalsSud university